Shitara, K., Wainberg, Z. A., Tabernero, J., Cutsem, E. V., Coutzac, C., Fouchardière, C. D. L., Lee, J., Rha, S. Y., Kang, Y., Fanning, P., An, G., Jin, F., Forgie, A. J., Pons, J., Tsiatis, A., Randolph, S., Lee, K. (2025). Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.332